LY2874455 has been used in trials studying the treatment of Advanced Cancer.

FGFR3:6.4 nM, FGFR4:6 nM, FGFR1:2.8 nM, FGFR2:2.6 nM, VEGFR2:7 nM

在携带RT-112,OPM-2（DSMZ）,SNU-16或NCI-H460异种移植物的小鼠中,LY2874455（3 mg/kg,口服）导致肿瘤生长的剂量依赖性抑制.LY2874455在小鼠心脏组织中,表现出对FGF诱导的Erk磷酸化的有效抑制,TED50和TED90值分别为1.3 和 3.2 mg/kg.

LY2874455在KMS-11,OPM-2,SNU-16和KATO-III细胞中显示FGFR依赖性抗增殖作用。在RT-112细胞,HUVECs,KATO-III细胞和SNU-16细胞中,LY2874455抑制FGF/FGFR介导的信号传导活性。

Biochemical filter-binding assays for detection of FGFR phosphorylation activities : Reaction mixtures contains 8 mM Tris-HCl (pH 7.5), 10 mmol/L HEPES, 5 mM dithiothreitol, 10 μM ATP, 0.5 μCi 33P-ATP, 10 mM MnCl2, 150 mM NaCl, 0.01% Triton X-100, 4% dimethyl sulfoxide, 0.05 mg/mL poly(Glu:Tyr) (4:1, average molecular weight of 20–50 kDa), and 7.5, 7.5, and 16 ng of FGFR1, FGFR3, and FGFR4, respectively, and are incubated at room temperature for 30 minutes followed by termination with 10% H3PO4. The reaction mixtures are transferred to 96-well MAFB filter plates that are washed 3 times with 0.5% H3PO4. After air-drying, the plates are read with a Trilux reader.

Cells (2,000 per well) are first grown in RPMI for 6 hours and treated with LY2874455 at 37 ℃ for 3 days. The cells are stained at 37℃ for 4 hours and then solubilized at 37℃ for 1 hour. Finally, the plate is read at 570 nm using a plate reader (Spectra Max Gemini XS). (Only for Reference)